Page 115 - CIBEREHD-2015-cast

Publicaciones científicas más relevantes
Grupos de Investigación
diaz-heRReRo M.M., del caMPo j.a., caRboneRo-aGuilaR P., veGa-PéRez j.M., iGlesias-GueRRa F., PeRina n i. et al. THDP17 decreases ammonia production through gluta- minase inhibition. A new drug for hepatic encephalopathy therapy. PLoS ONE. 2014;9(10).
eslaM M., leunG R., RoMeRo-GóMez M., ManGia a., iRvinG W.l., sheRidan d. et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology. 2014;61(2):235-241.
aFdhal n., zeuzeM s., KWo P., chojKieR M., Gitlin n., Puo- ti M. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine. 2014;370(20):1889-1898.
RoMeRo-GóMez M., aMPueRo j.. Deciphering the spec- trum of low-grade hepatic encephalopathy in clinical prac- tice. Gastroenterology. 2014;146(4):887-890.
joveR-cobos M., noiRet l., lee K., shaRMa v., habte- sion a., RoMeRo-GóMez M. et al. Ornithine phenylace- tate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammo- nia levels in bile duct ligated rats. Journal of Hepatology. 2014;60(3):545-553.
Institución: Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
Contacto: Hospital Virgen del Rocío · Avda. Manuel Siurot, s/n. 41013 Sevilla · E.mail: [email protected]
CIBEREHD I Memoria anual 2015 I 115